A recent study indicates that people who come off new GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds far faster than those who stop conventional lifestyle regimens.
Research printed in a prominent health publication shows that while overweight people can lose substantial amounts of their total mass while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"Users using such medications should be aware of the risk of quick rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a return to pre-treatment weight in about one and a half years.
Weighing Treatments
The research, which examined dozens of trials involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with conventional dieting.
Researchers point out that people who lose weight through diet and exercise typically have a less rapid creep back—approximately 100 grams monthly—after stopping.
Explaining the Fast Rebound
Nutrition scientists suggest the mechanism of the drugs is key to understanding the heightened rebound.
GLP-1 drugs mimic a natural hormone called GLP-1, which controls hunger.
"Artificially providing the hormone levels several times higher than normal could lead to the body to produce less of its own natural GLP-1, and could diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement means appetite is uncontrolled, making overeating much more probable."
An Ongoing Disease?
The NHS recommend the injections for people with weight-linked medical conditions, alongside recommended lifestyle changes.
Many experts say that, due to the likelihood of relapse, the therapy is often life-long.
This perspective is echoed by drug manufacturers, who state that the findings "emphasize the chronic nature of obesity," comparing it to managing diseases like high blood pressure.
User Accounts
People who have stopped the medication report a powerful return of appetite.
"It was like a trigger that goes on and you become ravenous," said a patient.
This challenge is compounded if patients have not established lasting dietary or behavioural modifications during treatment.
Widespread Adoption
Survey data show that millions of people in the UK have tried weight-loss jabs in the past year, with desire being substantial.
- Adoption is more common among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Ultimately, researchers emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a magic fix and long-term success likely depends on combined behavioural management.
